Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

638
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
638

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review of Haematological Toxicities in Well-Differentiated Neuroendocrine Tumours: A Case Report and Comprehensive Review of the Literature.

Journal of clinical medicine·2026
Same author

Insights into ctDNA assessment to detect minimal residual disease (MRD) in localized colorectal cancer.

Scientific reports·2026
Same author

Long-term survival and biomarkers of immunotherapy in small cell lung cancer: a systematic review.

Translational lung cancer research·2026
Same author

PD-1/LAG-3 signaling rewires T-cells via MYC inhibition.

Signal transduction and targeted therapy·2026
Same author

The EORTC updated breast cancer quality of life questionnaire EORTC QLQ-BR42: A psychometric study with Spanish patients.

BMC cancer·2026
Same author

The Experience of Spanish Cancer Patients and Professionals With Quality of Life Assessment in Clinical Practice.

Journal of patient experience·2026

Related Experiment Video

Updated: Aug 22, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

489

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy.

David Escors1, Ana Bocanegra1, Luisa Chocarro1

  • 1Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Hospital Universitario de Navarra-UPNA-IdISNA, Irunlarrea 3, 31008 Pamplona, Spain.

International Journal of Molecular Sciences
|November 11, 2022
PubMed
Summary

Immune checkpoint inhibitors like PD-L1/PD-1 blockade show promise in cancer treatment. This review highlights the crucial role of CD4 T cells and their memory subsets in predicting immunotherapy response.

Keywords:
T lymphocytesbiomarkerimmune checkpoint

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Related Experiment Videos

Last Updated: Aug 22, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

489
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Area of Science:

  • Immunology
  • Cancer Biology
  • Medical Science

Background:

  • PD-L1/PD-1 blockade immunotherapy has revolutionized cancer treatment.
  • Mechanisms of efficacy and treatment failure remain incompletely understood.
  • Systemic immunity is crucial for successful immunotherapy.

Purpose of the Study:

  • To review the contribution of CD4 T cells to anti-tumor immunity.
  • To discuss CD4 T cell subsets in PD-L1/PD-1 blockade immunotherapy.
  • To explore CD4 T cell memory subsets as predictors of response.

Main Methods:

  • Literature review and synthesis of existing evidence.
  • Analysis of studies in patients and mouse models.
  • Focus on CD4 T cell subsets and their functions.

Main Results:

  • CD4 T cells play a significant role in anti-tumor responses.
  • Specific CD4 T cell subsets are linked to effective PD-L1/PD-1 blockade.
  • Peripheral CD4 T cell memory subsets may predict treatment outcomes.

Conclusions:

  • CD4 T cells are integral to anti-tumor immunity and immunotherapy efficacy.
  • Understanding CD4 T cell subsets can optimize cancer treatment strategies.
  • CD4 T cell memory subsets offer potential as predictive biomarkers for immunotherapy.